Obstruction naproxen

C. Albrecht, B. N. Melgert, J. Reichen, K. Poelstra, and D. K. F. Meijer, Effect of chronic bile duct obstruction and LPS upon targeting of naproxen to the fiver using naproxen-albumin conjugate, J. Drug Target 6 105-117 (1998). 

In the VIGOR study, 8076 patients with rheumatoid arthritis were randomly assigned to receive rofecoxib 50 mg/day or naproxen 500 mg bd. The primary endpoint was a confirmed clinical upper gastrointestinal event (gastroduodenal perforation or obstruction, upper gastrointestinal bleeding, and symptomatic gastroduodenal ulcer). 

Overall, confirmed upper gastrointestinal events occurred in 177 patients, 56 with rofecoxib n — 4047), and 121 in those taking naproxen n — 4029). In 53 of these patients (16 taking rofecoxib and 37 taking naproxen) the event was complicated. That means that during a median follow-up of 9.0 months, there were 2.1 confirmed gastrointestinal events per 100 patient-years with rofecoxib compared with 4.5 per 100 patient-years with naproxen (RR = 0.5 95% Cl = 0.2, 0.8). The respective rates of complicated ulcers (perforation, obstruction, and bleeding) were 0.6 per 100 patient-years and 1.4 per 100 patient-years (RR = 0.4 95% Cl = 0.2, 0.8). 

---